Welcome to our dedicated page for Forte Biosciences news (Ticker: FBRX), a resource for investors and traders seeking the latest updates and insights on Forte Biosciences stock.
Forte Biosciences, Inc. reports developments tied to FB102, its proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related diseases. Recurring updates cover clinical development in celiac disease, non-segmental vitiligo and alopecia areata, including regulatory designations such as Fast Track status in celiac disease.
Company news also includes quarterly and annual financial results, research and development spending tied to FB102, public financing activity, investor meeting participation and Nasdaq-required disclosures for equity inducement awards under its 2020 Inducement Equity Incentive Plan.
Forte Biosciences (NASDAQ: FBRX) reported its second quarter 2022 results, ending with $38.5 million in cash. The company is advancing its pipeline for autoimmune diseases, targeting markets exceeding $6 billion. Notable appointments include Hubert Chen, M.D. as Chief Scientific Officer and Stephen Doberstein, Ph.D. to the Board. Research and development costs decreased due to the winding down of the FB-401 program. Despite a net loss of $3.0 million for the quarter, Forte aims to launch its lead molecule, FB-102, in late 2023 or early 2024.
Forte Biosciences, Inc. (NASDAQ: FBRX) announced the appointment of Dr. Hubert Chen as Chief Scientific Officer and President. Dr. Chen brings extensive experience in drug development, previously serving as Chief Medical Officer at Metacrine and Chief Scientific and Medical Officer at Pfenex. His leadership is expected to strengthen Forte's focus on autoimmune diseases, particularly with their lead product FB-102. CEO Paul Wagner expressed confidence in Dr. Chen's expertise during this pivotal time for the company.
Forte Biosciences, Inc. (NASDAQ: FBRX) has announced an equity inducement award of 250,000 shares of common stock to Dr. Hubert Chen, who has joined as Chief Scientific Officer and President. This award, part of the company's 2020 Inducement Equity Incentive Plan, vests over four years, with 25% vesting after one year. Forte is focused on developing treatments for autoimmune diseases, with its lead product, FB-102, being proprietary. The company cautions that forward-looking statements are subject to risks that may affect actual results.
Forte Biosciences (NASDAQ: FBRX) recently announced its first quarter 2022 results, ending with approximately $40 million in cash. The company is shifting focus to develop FB-102, a novel treatment for autoimmune diseases, with potential market value exceeding $6 billion. The company appointed Stephen Doberstein, Ph.D. and Barbara Finck, M.D. to its Board of Directors, enhancing leadership experience. Research and development expenses have decreased significantly, with a net loss of $2.57 million for the quarter, an improvement from $4.80 million year-over-year.
Forte Biosciences, Inc. (NASDAQ: FBRX) announced that the topline data from its Phase 2 clinical trial of FB-401 for atopic dermatitis did not achieve statistical significance for the primary endpoint, EASI-50. While positive trends were noted in secondary endpoints, such as EASI-90, achieving success rates of 27.6% versus 20.5% in the control arm, the trial's primary endpoint showed 58% success compared to 60% in the placebo group. Following this setback, the company will not advance FB-401 and will update investors on future plans in the coming months. As of June 30, 2021, cash reserves were $50.8 million.
Forte Biosciences, Inc. (NASDAQ: FBRX) is set to announce topline data from its Phase 2 trial of FB-401 for treating atopic dermatitis on September 7, 2021. This follows the completion of a Phase 1/2a study showing promising safety and efficacy in pediatric and adult patients. The upcoming data release coincides with a conference call on the same day. Forte aims to meet the unmet need for effective therapies in pediatric atopic dermatitis, particularly after initiating a multi-center, placebo-controlled trial, which began in September 2020.
Forte Biosciences, Inc. (NASDAQ: FBRX) announced an equity inducement award for purchasing 90,000 shares of common stock to a new non-executive employee. This grant, approved by the Compensation Committee, serves as a material inducement for employment and will vest over four years. The award aligns with the terms of Forte's 2021 Equity Incentive Plan. Forte is a clinical-stage biopharmaceutical company focused on developing FB-401 for treating inflammatory skin diseases, including pediatric atopic dermatitis, with ongoing clinical trials demonstrating safety and activity across various age groups.
Forte Biosciences, Inc. (NASDAQ: FBRX) announced the issuance of an equity inducement award to a new non-executive employee, granting options to purchase 15,000 shares of common stock. This award is a requirement of NASDAQ Listing Rule 5635(c)(4) and will vest over four years. The company, focused on developing FB-401 for inflammatory skin diseases, has completed a Phase 1/2a study showing safety and efficacy in patients aged 3 and older. A multi-center, placebo-controlled trial of FB-401 is ongoing.
Forte Biosciences, Inc. (NASDAQ: FBRX) announced the issuance of an equity inducement award of 25,000 shares to a new non-executive employee. This grant aims to encourage employment and vests over four years. The company, focused on developing FB-401 for treating inflammatory skin diseases, has completed a Phase 1/2a study showing safety and activity across various age groups. A Phase 2 clinical trial has also been initiated for pediatric and adult atopic dermatitis patients. The company emphasizes that forward-looking statements may differ from actual outcomes due to various risks.
Forte Biosciences, Inc. (NASDAQ: FBRX) reported its first quarter 2021 results on May 10, highlighting significant progress in its clinical trial for FB-401, targeting atopic dermatitis. The trial has completed enrollment with 154 subjects, with topline results expected in Q3 2021. The company ended Q1 2021 with approximately $54.8 million in cash, sufficient for operations over the next year. Operating expenses rose due to increased R&D and administrative costs, leading to a net loss of $4.8 million, or $0.36 per share.